BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang X, Li A, Xie C, Zhang Y, Liu X, Xie Y, Wu B, Zhou S, Huang X, Ma Y, Cao W, Xu R, Shen J, Huo Z, Cai S, Liang Y, Ma D. The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway. Nanoscale Res Lett 2020;15:63. [PMID: 32219609 DOI: 10.1186/s11671-020-3289-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang X, He C, Xiang G. Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy. Cancer Lett 2022:S0304-3835(22)00020-9. [PMID: 35041892 DOI: 10.1016/j.canlet.2022.01.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mittal D, Niveria K, Verma AK. Nanotechnology-based targeted delivery systems for protein kinase inhibitors in Cancer therapy. Protein Kinase Inhibitors 2022. [DOI: 10.1016/b978-0-323-91287-7.00005-3] [Reference Citation Analysis]
3 Alemi F, Raei Sadigh A, Malakoti F, Elhaei Y, Ghaffari SH, Maleki M, Asemi Z, Yousefi B, Targhazeh N, Majidinia M. Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk. J Cell Physiol 2021. [PMID: 34515349 DOI: 10.1002/jcp.30573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
4 Xu R, Zhang Y, Li A, Ma Y, Cai W, Song L, Xie Y, Zhou S, Cao W, Tang X. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway. Mol Med Rep 2021;24:508. [PMID: 33982772 DOI: 10.3892/mmr.2021.12147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 2021;11:5464-90. [PMID: 33859758 DOI: 10.7150/thno.54822] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 20.0] [Reference Citation Analysis]
6 Yang H, Jing H, Han X, Tan H, Cheng W. Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma. Drug Des Devel Ther 2021;15:531-42. [PMID: 33603343 DOI: 10.2147/DDDT.S296880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Ma Y, Xu R, Liu X, Zhang Y, Song L, Cai S, Zhou S, Xie Y, Li A, Cao W, Tang X. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. Int J Med Sci 2021;18:1456-64. [PMID: 33628103 DOI: 10.7150/ijms.51256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
8 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
9 Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci 2020;7:193. [PMID: 32974385 DOI: 10.3389/fmolb.2020.00193] [Cited by in Crossref: 130] [Cited by in F6Publishing: 150] [Article Influence: 65.0] [Reference Citation Analysis]